ICON PLC
ICLR Healthcare Diagnostics & Research
ICON PLC’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.76% from fiscal 2024. In the quarter to June 2026, revenue grew 1.20%, EPS fell 59.3%, free cash flow grew 109.7% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow ICLR
ICON PLC (ICLR) EV/Sales
As of 16 October 2026, ICON PLC (ICLR) trades at a EV/Sales of 1.9×. Over the past ten years it has ranged from 1.1× (February 2026) to 6.9× (December 2021); the current reading is higher than 8% of that period. That is below the Diagnostics & Research industry median of 5.5× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.1× | (16.19%) |
| FY2024 | 2.5× | (24.33%) |
| FY2023 | 3.3× | 25.16% |
| FY2022 | 2.6× | (43.99%) |
| FY2021 | 4.6× | 32.12% |
| FY2020 | 3.5× | 8.04% |
| FY2019 | 3.3× | 16.76% |
| FY2018 | 2.8× | (24.99%) |
| FY2017 | 3.7× | 35.65% |
| FY2016 | 2.7× | (14.95%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.9× | 41.95% |
| Mar 2026 | 1.3× | (34.99%) |
| Dec 2025 | 2.1× | 0.85% |
| Sep 2025 | 2.0× | 13.08% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ICLR ICON PLC | 1.9× |
| LH Labcorp Holdings Inc. compare | 2.2× |
| DGX Quest Diagnostics Incorporated compare | 2.7× |
| CRL Charles River Laboratories International, Inc. compare | 4.2× |
| QGEN QIAGEN N.V. compare | 4.9× |
| MEDP Medpace Holdings, Inc. compare | 6.1× |
| RVTY Revvity Inc. compare | 6.6× |
| GH Guardant Health, Inc. compare | 18.2× |
| TWST Twist Bioscience Corporation compare | 18.8× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)